Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Glioblastoma 2Prostatic Neoplasms 1Oligodendroglioma 1Neuroblastoma 1Neoplasms 1Lymphoma, Follicular 1Glioma 1Brain Neoplasms 1Astrocytoma 1

Interventions

enzalutamide 94Magnetic Resonance Spectroscopy 85Specimen Handling 66Prednisone 63Androgen Antagonists 59Abiraterone Acetate 57apalutamide 55Radiosurgery 52darolutamide 48Radiotherapy 47Leuprolide 46abiraterone 45Docetaxel 42Pluvicto 32Biopsy 31acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 30Radiation 30relugolix 28Surveys and Questionnaires 28gallium 68 PSMA-11 26Standard of Care 26pembrolizumab 25Goserelin 25Triptorelin Pamoate 24Gonadotropin-Releasing Hormone 23bicalutamide 22Brachytherapy 21Carboplatin 20cabazitaxel 19X-Rays 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Ketoconazole × 1 year × Clear all
NCT00859781 2026-04-08

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer

Weill Medical College of Cornell University

Phase 2 Active not recruiting
55 enrolled 11 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡